Literature DB >> 10203866

Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders.

M Gasior1, R B Carter, J M Witkin.   

Abstract

Neuroactive steroids are a novel class of positive allosteric modulators of the GABAA receptor. Although neuroactive steroids are endogenous neuronal modulators, synthetic entities with improved oral bioavailability have recently been developed. These compounds demonstrate efficacy as anticonvulsants against a range of convulsant stimuli and demonstrate anti-epileptogenic activity in a kindling model of epilepsy. Efficacy has also been reported in preclinical models of anxiety, insomnia, migraine and drug dependence. Clinical evidence to date is generally supportive of these findings and indicates that neuroactive steroids are generally well tolerated. Taken as a whole, current data suggest that neuroactive steroids could have a future role in clinical practice. In this article, Maciej Gasior, Richard Carter and Jeffrey Witkin review preclinical and clinical evidence that forms the basis for predicting the potential therapeutic application of neuroactive steroids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203866     DOI: 10.1016/s0165-6147(99)01318-8

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  45 in total

1.  Ischemic insult to cerebellar Purkinje cells causes diminished GABAA receptor function and allopregnanolone neuroprotection is associated with GABAA receptor stabilization.

Authors:  Melissa H Kelley; Noriko Taguchi; Ardalan Ardeshiri; Masayuki Kuroiwa; Patricia D Hurn; Richard J Traystman; Paco S Herson
Journal:  J Neurochem       Date:  2008-09-18       Impact factor: 5.372

2.  Neurosteroid modulators of GABA(A) receptors differentially modulate Ethanol intake patterns in male C57BL/6J mice.

Authors:  Matthew M Ford; Jeffrey D Nickel; Tamara J Phillips; Deborah A Finn
Journal:  Alcohol Clin Exp Res       Date:  2005-09       Impact factor: 3.455

3.  Non-stereo-selective cytosolic human brain tissue 3-ketosteroid reductase is refractory to inhibition by AKR1C inhibitors.

Authors:  Stephan Steckelbroeck; Dieter Lütjohann; David R Bauman; Michael Ludwig; Anke Friedl; Volkmar H J Hans; Trevor M Penning; Dietrich Klingmüller
Journal:  Biochim Biophys Acta       Date:  2010-07-29

4.  Heterogeneity of hippocampal GABA(A) receptors: regulation by corticosterone.

Authors:  M Orchinik; S S Carroll; Y H Li; B S McEwen; N G Weiland
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

5.  Replacement with GABAergic steroid precursors restores the acute ethanol withdrawal profile in adrenalectomy/gonadectomy mice.

Authors:  K R Kaufman; M A Tanchuck; M N Strong; D A Finn
Journal:  Neuroscience       Date:  2010-01-06       Impact factor: 3.590

6.  Inhibition of 5alpha-reduced steroid biosynthesis impedes acquisition of ethanol drinking in male C57BL/6J mice.

Authors:  Matthew M Ford; Naomi Yoneyama; Moriah N Strong; Andrea Fretwell; Michelle Tanchuck; Deborah A Finn
Journal:  Alcohol Clin Exp Res       Date:  2008-06-28       Impact factor: 3.455

7.  Effects of allopregnanolone on the reinstatement of cocaine-seeking behavior in male and female rats.

Authors:  Justin J Anker; Nathan A Holtz; Natalie Zlebnik; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2008-11-08       Impact factor: 4.530

Review 8.  [Significance of GABAA receptors for the pathophysiology and therapy of panic disorders].

Authors:  R Rupprecht; P Zwanzger
Journal:  Nervenarzt       Date:  2003-06-24       Impact factor: 1.214

Review 9.  Hormones, nicotine, and cocaine: clinical studies.

Authors:  Nancy K Mello
Journal:  Horm Behav       Date:  2009-10-14       Impact factor: 3.587

10.  Kinetic and structural determinants for GABA-A receptor potentiation by neuroactive steroids.

Authors:  Gustav Akk; Douglas F Covey; Alex S Evers; Steven Mennerick; Charles F Zorumski; Joe Henry Steinbach
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.